Connection

GLORIA ECHEVERRIA to Humans

This is a "connection" page, showing publications GLORIA ECHEVERRIA has written about Humans.
Connection Strength

0.187
  1. Deregulation of mitochondrial gene expression in cancer: mechanisms and therapeutic opportunities. Br J Cancer. 2024 Nov; 131(9):1415-1424.
    View in: PubMed
    Score: 0.023
  2. Avoiding Extinction: Cancer-Associated Fibroblasts Help Triple-Negative Breast Cancer Outrun Chemotherapy. Cancer Res. 2023 11 15; 83(22):3667-3669.
    View in: PubMed
    Score: 0.022
  3. Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment. Oncogene. 2023 03; 42(14):1117-1131.
    View in: PubMed
    Score: 0.021
  4. Methodological Advancements for Investigating Intra-tumoral Heterogeneity in Breast Cancer at the Bench and Bedside. J Mammary Gland Biol Neoplasia. 2020 12; 25(4):289-304.
    View in: PubMed
    Score: 0.018
  5. Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state. Sci Transl Med. 2019 04 17; 11(488).
    View in: PubMed
    Score: 0.016
  6. High-resolution clonal mapping of multi-organ metastasis in triple negative breast cancer. Nat Commun. 2018 11 29; 9(1):5079.
    View in: PubMed
    Score: 0.016
  7. Muscleblind-like 1 activates insulin receptor exon 11 inclusion by enhancing U2AF65 binding and splicing of the upstream intron. Nucleic Acids Res. 2014 Feb; 42(3):1893-903.
    View in: PubMed
    Score: 0.011
  8. RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res. 2012 Jun 26; 1462:100-11.
    View in: PubMed
    Score: 0.010
  9. Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
    View in: PubMed
    Score: 0.007
  10. Tumor microenvironment transcriptional activity enables robust stratification of chemotherapy response in triple-negative breast cancer. Cell Rep Med. 2026 Feb 17; 7(2):102610.
    View in: PubMed
    Score: 0.007
  11. An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Na?ve and Longitudinal Samples during Neoadjuvant Chemotherapy. Cancer Res. 2025 Nov 03; 85(21):4062-4080.
    View in: PubMed
    Score: 0.006
  12. Xenomake: a pipeline for processing and sorting xenograft reads from spatial transcriptomic experiments. Bioinformatics. 2024 Nov 01; 40(11).
    View in: PubMed
    Score: 0.006
  13. Evolution of cisplatin resistance through coordinated metabolic reprogramming of the cellular reductive state. Br J Cancer. 2023 06; 128(11):2013-2024.
    View in: PubMed
    Score: 0.005
  14. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
    View in: PubMed
    Score: 0.005
  15. Pharmacologic profiling of patient-derived xenograft models of primary treatment-na?ve triple-negative breast cancer. Sci Rep. 2020 10 21; 10(1):17899.
    View in: PubMed
    Score: 0.004
  16. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer. Breast Cancer Res. 2016 Jan 27; 18(1):13.
    View in: PubMed
    Score: 0.003
  17. The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature. 2015 Sep 17; 525(7569):384-8.
    View in: PubMed
    Score: 0.003
  18. Identification of MBNL1 and MBNL3 domains required for splicing activation and repression. Nucleic Acids Res. 2011 Apr; 39(7):2769-80.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.